Cargando…
CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations
Residual androgen receptor (AR)-signaling and presence of cancer stem-like cells (SCs) are the two emerging paradigms for clinically challenging castration-resistant prostate cancer (CRPC). Therefore, identification of AR-target proteins that are also overexpressed in the cancer SC population would...
Autores principales: | Khanna, Anchit, Rane, Jayant K., Kivinummi, Kati K., Urbanucci, Alfonso, Helenius, Merja A., Tolonen, Teemu T., Saramäki, Outi R., Latonen, Leena, Manni, Visa, Pimanda, John E., Maitland, Norman J., Westermarck, Jukka, Visakorpi, Tapio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4637312/ https://www.ncbi.nlm.nih.gov/pubmed/25965834 |
Ejemplares similares
-
ETS1 Mediates MEK1/2-Dependent Overexpression of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) in Human Cancer Cells
por: Khanna, Anchit, et al.
Publicado: (2011) -
Androgen regulation of the androgen receptor coregulators
por: Urbanucci, Alfonso, et al.
Publicado: (2008) -
Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer
por: Annala, Matti, et al.
Publicado: (2015) -
Proteomics of prostate cancer – revealing how cancer cells master their messy genomes
por: Latonen, Leena, et al.
Publicado: (2018) -
The expression of AURKA is androgen regulated in castration-resistant prostate cancer
por: Kivinummi, Kati, et al.
Publicado: (2017)